07:00 , Sep 15, 2014 |  BC Week In Review  |  Company News

Roche sales and marketing update

Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland   Business: Diagnostic   Roche launched its next-generation real-time PCR cobas 6800 and 8800 systems in markets accepting the CE Mark, including Europe, Latin America, the Middle East, Africa and...
07:00 , Jun 16, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones BioDelivery Sciences International Inc. (NASDAQ:BDSI) gained $2.36 (24%) to $12.36 last week after FDA approved Bunavail buprenorphine naloxone as maintenance treatment for opioid dependence. BioDelivery said it plans to launch the product late...
08:00 , Mar 3, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Anika Therapeutics Inc. (NASDAQ:ANIK) rose $11.43 (33%) to $45.90 on Wednesday after saying FDA approved Monovisc to treat osteoarthritis of the knee. Monovisc is a single injection that delivers hyaluronic acid from a...
08:00 , Feb 3, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones ALK-Abello A/S (CSE:ALK-B) gained DKK5 to DKK723 last week after FDA's Allergenic Products Advisory Committee voted 6-2, with one abstention, that available data support the efficacy of Ragwitek ragweed Allergy Immunotherapy Tablet (AIT)...
08:00 , Nov 18, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Algeta ASA (OSE:ALGETA) was off NOK4.60 to NOK263.40 on Friday after the European Commission approved an MAA from partner Bayer AG (Xetra:BAYN) for Xofigo radium-223 dichloride to treat adults with castration-resistant prostate cancer...
07:00 , Sep 23, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Algeta ASA (OSE:ALGETA) added NOK3.40 to NOK244.40 on Friday after EMA's CHMP recommended approval of Xofigo radium-223 dichloride to treat adults with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral...
07:00 , Sep 16, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) was off $0.07 to $114.14 on Friday after Japan's Ministry of Health, Labor and Welfare (MHLW) approved an NDA for Soliris eculizumab to treat atypical hemolytic uremic syndrome (aHUS)....
07:00 , Sep 9, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones ALK-Abello A/S (CSE:ALK-B) gained DKK8.50 to DKK482 last week after reporting that FDA's Allergenic Products Advisory Committee will meet on Nov. 6 to discuss a BLA from partner Merck & Co. Inc. (NYSE:MRK)...
07:00 , Aug 19, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Galectin Therapeutics Inc. (NASDAQ:GALT) rose $1.21 (22%) to $6.78 on Monday after FDA granted Fast Track designation to GR-MD-02 to treat non-alcoholic steatohepatitis (NASH) with advanced hepatic fibrosis. The galectin-3 (LGALS3) and galectin-1...
07:00 , Jul 29, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Forest Laboratories Inc. (NYSE:FRX) was up $0.42 to $44.41 on Friday after FDA approved Fetzima levomilnacipran to treat major depressive disorder (MDD) in adults. The company said the product will be available in...